Smartwatch-Based Blood Pressure Measurement Demonstrates Insufficient Accuracy.

ABSTRACT:

Background

Novel smartwatch-based cuffless blood pressure (BP) measuring devices are coming to market and receive FDA and CE labels. These devices are often insufficiently validated for clinical use. This study aims to investigate a recently CE-cleared smartwatch using cuffless BP measurement in a population with normotensive and hypertensive individuals scheduled for 24-h BP measurement.

Methods

Patients that were scheduled for 24-h ambulatory blood pressure monitoring (ABPM) were recruited and received an additional Samsung Galaxy Watch Active 2 smartwatch for simultaneous BP measurement on their opposite arm. After calibration, patients were asked to measure as much as possible in a 24-h period. Manual activation of the smartwatch is necessary to measure the BP. Accuracy

SUBMITTER: Falter M 

PROVIDER: S-EPMC9309348 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature